Quick Answer
Altimmune, Inc. reported Net Income of -$88.09 million for fiscal year 2025.
Altimmune, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$88.09M | +7.3% |
| 2024 | -$95.06M | -7.5% |
| 2023 | -$88.45M | -4.4% |
| 2022 | -$84.71M | +12.7% |
| 2021 | -$97.09M | -98.0% |
| 2020 | -$49.04M | -139.0% |
| 2019 | -$20.52M | +47.6% |
| 2018 | -$39.17M | +15.6% |
| 2017 | -$46.43M | -318.7% |
| 2016 | -$11.09M | -222.2% |
| 2015 | -$3.44M | +65.4% |
| 2014 | -$9.96M | +15.0% |
| 2013 | -$11.72M | -138.2% |
| 2012 | -$4.92M | -29.6% |
| 2011 | -$3.80M | +89.1% |
| 2010 | -$34.85M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.01M | +16.8% | +14.1% |
| June 30, 2025 | -$22.15M | +10.1% | -13.1% |
| March 31, 2025 | -$19.57M | +19.8% | +14.3% |
| September 30, 2024 | -$22.84M | -10.5% | +7.3% |
| June 30, 2024 | -$24.64M | -53.4% | -1.0% |
| March 31, 2024 | -$24.39M | -21.5% | -18.0% |
| September 30, 2023 | -$20.67M | +12.1% | -28.7% |
| June 30, 2023 | -$16.06M | +20.1% | +20.0% |
- Altimmune, Inc. showed an increase of +7.3% in Net Income compared to the prior fiscal year.
- Over the 2010–2025 period, Altimmune, Inc.’s net income has declined by 152.8% (from -$34.85 million to -$88.09 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: